 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

ProMIS Neurosciences, Inc. (NASDAQ:PMN  Get Free Report)s stock price traded up 0.5% during trading on Friday . The stock traded as high as $2.09 and last traded at $2.01. 11,876 shares...

ProMIS Neurosciences (NASDAQ:PMN) Trading 0.5% Higher

See the rest of the story here.

thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...

ProMIS Neurosciences files $100M mixed securities shelf

ProMIS Neurosciences files to sell 22.13M shares of common stock for holders

At-the-Market fundraise to support Company through several potentially value-creating milestones and beyondTORONTO, Ontario and CAMBRIDGE, Massachusetts, Sept. 08, 2023 (GLOBE NEWSWIRE) -- ProMIS...

ProMIS Neurosciences Closes $20.4 Million Private Placement Financing

TORONTO, Ontario and CAMBRIDGE, Massachusetts, Sept. 06, 2023 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (Nasdaq: PMN), a biotechnology company focused on the generation and development of...

ProMIS Neurosciences to Present at the H.C. Wainwright 25th Annual Global Investment Conference

ProMIS Neurosciences, Inc. (NASDAQ:PMN  Get Free Report) shares fell 4.9% on Thursday . The stock traded as low as $1.96 and last traded at $1.96. 17,865 shares changed hands during mid-day...

ProMIS Neurosciences (NASDAQ:PMN) Stock Price Down 4.9%

ProMIS Neurosciences, Inc. (NASDAQ:PMN  Get Free Report)s share price traded down 4.9% during trading on Thursday . The company traded as low as $1.96 and last traded at $1.96. 17,865...

ProMIS Neurosciences scales 31% on $20.4M private placement

ProMIS Neurosciences GAAP EPS of -$0.27

Presented compelling preclinical data supporting therapeutic potential of PMN310 to treat Alzheimer s disease, and the promise of disease prevention with a computationally derived Alzheimer s disease...

ProMIS Neurosciences Announces Second Quarter 2023 Financial Results and Recent Highlights

ProMIS Neurosciences, Inc. engages in the discovery and development of precision medicine solutions for early detection and effective treatment of neurodegenerative diseases. It focuses on the progression of Alzheimer's disease, amyotrophic lateral sclerosis, and Parkinson's disease. The company was founded by Neil Cashman and Vigen Nazarian on January 23, 2004 and is headquartered in Toronto, Canada.

Watchers	103
52-Wk Low	$1.50
52-Wk High	$8.95

Market Cap	$16.47M
Volume (M)	11,191.00
52-Wk High	$8.95
52-Wk Low	$1.50

PMN ProMIS Neurosciences

About

Feed

News

Fundamentals